

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

|                       |  |
|-----------------------|--|
| <b>Name of entity</b> | <b>BARD1 LIFE SCIENCES LIMITED (BD1)</b> |
| <b>ABN</b>            | <b>58 009 070 384</b>                    |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                     |
|----------------------------|---------------------|
| <b>Name of Director</b>    | DR GEOFFREY CUMMING |
| <b>Date of last notice</b> | 4 August 2020       |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|  |   |
|--|---|
| <b>Direct or indirect interest</b>   | Indirect  |
| <b>Nature of indirect interest (including registered holder)</b><br>Note: Provide details of the circumstances giving rise to the relevant interest. | Indirect<br>Jamelys Superannuation Fund   |
| <b>Date of change</b>  | 17 August 2020  |
| <b>No. of securities held prior to change</b>  | 3,472,802*<br>Nil#  |
| <b>Class</b>   | *Ordinary Fully Paid Shares<br>#Unlisted Incentive Options  |
| <b>Number acquired/despached</b>   | Nil*<br>1,560,000#  |
| <b>Number disposed</b>   | Nil   |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and estimated valuation  | BD1 Incentive Options issued per Scheme of Arrangement between BD1 and Sienna Cancer Diagnostics Limited (SDX), exchange of SDX options |

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

|   |  |
|---|--|
| <b>No. of securities held after change</b>  | 3,472,802 ordinary fully paid shares<br>1,560,000 unlisted BD1 incentive options |
| <b>Nature of change</b><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | BD1 incentive options acquired per the Scheme of Arrangement                     |

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|  |     |
|--|-----|
| <b>Detail of contract</b>  | N/A |
| <b>Nature of interest</b>  | N/A |
| <b>Name of registered holder (if issued securities)</b>  | N/A |
| <b>Date of change</b>  | N/A |
| <b>No. and class of securities to which interest related prior to change</b><br>Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| <b>Interest acquired</b>   | N/A |
| <b>Interest disposed</b>   | N/A |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and an estimated valuation   | N/A |
| <b>Interest after change</b>   | N/A |

#### Part 3 – <sup>+</sup>Closed period

|   |     |
|---|-----|
| <b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b> | No  |
| <b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>  | N/A |
| <b>If prior written clearance was provided, on what date was this provided?</b>   | N/A |

Dated: 29/07/2019

<sup>+</sup> See chapter 19 for defined terms.